Business Context and Reporting Period
This Form 8-K Current Report was filed by Phreesia, Inc. on September 28, 2021. The filing addresses changes to the composition of the Board of Directors effective October 1, 2021.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The only financial data disclosed relates to director compensation and a related-party transaction:
- Director Compensation: Ramin Sayar received an Initial RSU Grant valued at $120,416 and a New Hire Grant valued at $170,000.
- Related-Party Transaction: The Company has paid Sumo Logic, Inc. (where Mr. Sayar is CEO) $549,605 since February 1, 2020, under existing software agreements.
Material Changes
The primary material change reported is the turnover of a Board member:
- Resignation: Cheryl Pegus, M.D., resigned from the Board effective October 1, 2021. The resignation was not due to any disagreement with the Company.
- Appointment: Ramin Sayar was appointed to the Board effective October 1, 2021, serving as a Class II director until the 2024 annual meeting.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding future performance. Regarding risks and contingencies:
- Related-Party Transaction Disclosure: The Company disclosed that Mr. Sayar is the CEO of Sumo Logic, Inc., a vendor. Management asserts that the terms and amounts paid to Sumo Logic are comparable to arm's length transactions.
- Compensation Terms: The New Hire Grant for Mr. Sayar vests over four years (25% annually), subject to continued service.
Investor Verification Checklist
- Verify the independence of the new director, Ramin Sayar, given his role as CEO of a vendor (Sumo Logic) receiving payments from Phreesia.
- Confirm the total value of outstanding RSU grants to the Board under the Second Amended and Restated Director Compensation Policy.
- Review the specific terms of the software agreements with Sumo Logic, Inc. to validate the arm's length nature of the $549,605 in payments.
- Check subsequent filings for the appointment of a replacement for the resigned director, Cheryl Pegus, M.D.